A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)
Clinical trial NCT04875195 · COMPLETED
Trial details
- NCT number
- NCT04875195
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-07
- Primary completion
- 2023-12-14
- Enrollment
- 66
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.